Broadly neutralizing antibodies (bNAbs) are thought to be the future for treating and preventing HIV infections. A bNAb recently characterized by Caltech researchers can neutralize HIV in different states—increasing the antibody's promise as a therapeutic.
Finding an anti-AIDS vaccine remains an elusive goal—partly because the HIV virus quickly mutates to evade the vaccine's antibodies. In a Watson Lecture on April 1, Caltech's Pamela J. Bjorkman will describe ways to neutralize that mutational advantage.
Researchers around the country are adopting a technique developed in the Caltech lab of Nobel Laureate David Baltimore to try to guard against infection. The method, called VIP, was originally designed to trigger an immune response to HIV.
"The method that we developed has now been validated in the most natural possible setting in a mouse," says David Baltimore, president emeritus and the Robert Andrews Millikan Professor of Biology at Caltech.
Researchers at Caltech are the first to have utilized high-resolution electron microscopy to look at HIV infection within the actual tissue of an infected organism, providing perhaps the most detailed characterization yet of HIV infection in the gut.
Years spent studying HIV in the lab were beginning to make Pamela Bjorkman feel disconnected from the possible impact of her work. So this summer she visited India, spending time with HIV-positive women and others who are at risk.
Rustem Ismagilov, the new John W. and Herberta M. Miles Professor of Chemistry and Chemical Engineering at Caltech, believes in the ability of science and technology to address significant societal problems—from the spread of HIV and drug resistance to bacterial imbalances in the gut.
Over the past year, researchers at Caltech, and around the world, have been studying a group of potent antibodies that have the ability to neutralize HIV in the lab; their hope is that they may learn how to create a vaccine that makes antibodies with similar properties. Now, biologists at Caltech led by Nobel Laureate David Baltimore have taken one step closer to that goal: they have developed a way to deliver these antibodies to mice and, in so doing, have effectively protected them from HIV infection.